Double-blind , placebo-controlled trial in HIV + with CD4 ( + ) T cells/L ( CD4 ) 200 randomized to receive the 23-valent pneumococcal polysaccharide vaccine ( PPV23 ) or placebo at enrollment , followed by placebo or PPV23 , respectively , 9-12 months later ( after 6 months of ART ) .